Pub Date : 2025-03-03DOI: 10.1016/s1470-2045(24)00632-6
Maria Jocelyn Kara Magsanoc-Alikpala, Aveline Marie D Ylanan, Cecilia Rivera-Montales, Juan Martin Magsanoc, Michelle Ann B Eala, Edward Christopher Dee
Section snippets
Ating Dibdibin: a programme for Filipinos with breast cancer
Founded and led primarily by survivors of breast cancer, ICanServe established a programme called Ating Dibdibin (Take Your Breast Care to Heart). Long before the enactment of the NICCA and release of WHO's Global Breast Cancer Initiative (GBCI), the programme has been in place since 2008 to promote prevention, early diagnosis, and timely access to treatment; to provide supportive and survivorship care; and to implement patient navigation to improve adherence. In the setting of the
Ating Dibdibin: community outcomes
Ating Dibdibin has been adopted by seven cities (Marikina City, Panabo City, Tagum City, San Juan City, Muntinlupa City, Taguig City, and Baguio City). In the city of Taguig, in which the Ating Dibdibin programme started in 2011, almost 200 000 women have attended lectures or forums, and more than 125 000 have been screened via clinical breast examination. Additionally, almost 6000 patients have had relevant findings on clinical breast examination and have subsequently undergone diagnostic
Empower the target group and understand their needs
As a survivor-led organisation, ICanServe understands the challenges and needs of Filipino patients with breast cancer. Financial toxicity at each level of the cancer continuum is a substantial barrier. ICanServe addresses financial toxicity by empowering both patients and local governments to access already available funding sources such as the Gender and Development Fund, which mandates a 10% allocation from government budgets for programmes such as Ating Dibdibin. Additionally, the programme
Conclusion
Ating Dibdibin can be a springboard to establish a breast cancer control programme that can branch out to other types of cancer. Other local government partners have used the same programme principles of the Ating Dibdibin programme for cervical cancer control.ICanServe's Ating Dibdibin programme offers valuable insights for countries facing similar challenges in breast cancer control, showing that patient-led efforts are not only viable but successful in low-income and middle-income settings.
{"title":"Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines","authors":"Maria Jocelyn Kara Magsanoc-Alikpala, Aveline Marie D Ylanan, Cecilia Rivera-Montales, Juan Martin Magsanoc, Michelle Ann B Eala, Edward Christopher Dee","doi":"10.1016/s1470-2045(24)00632-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00632-6","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Ating Dibdibin: a programme for Filipinos with breast cancer</h2>Founded and led primarily by survivors of breast cancer, ICanServe established a programme called Ating Dibdibin (Take Your Breast Care to Heart). Long before the enactment of the NICCA and release of WHO's Global Breast Cancer Initiative (GBCI), the programme has been in place since 2008 to promote prevention, early diagnosis, and timely access to treatment; to provide supportive and survivorship care; and to implement patient navigation to improve adherence. In the setting of the</section></section><section><section><h2>Ating Dibdibin: community outcomes</h2>Ating Dibdibin has been adopted by seven cities (Marikina City, Panabo City, Tagum City, San Juan City, Muntinlupa City, Taguig City, and Baguio City). In the city of Taguig, in which the Ating Dibdibin programme started in 2011, almost 200 000 women have attended lectures or forums, and more than 125 000 have been screened via clinical breast examination. Additionally, almost 6000 patients have had relevant findings on clinical breast examination and have subsequently undergone diagnostic</section></section><section><section><section><h2>Empower the target group and understand their needs</h2>As a survivor-led organisation, ICanServe understands the challenges and needs of Filipino patients with breast cancer. Financial toxicity at each level of the cancer continuum is a substantial barrier. ICanServe addresses financial toxicity by empowering both patients and local governments to access already available funding sources such as the Gender and Development Fund, which mandates a 10% allocation from government budgets for programmes such as Ating Dibdibin. Additionally, the programme</section></section></section><section><section><h2>Conclusion</h2>Ating Dibdibin can be a springboard to establish a breast cancer control programme that can branch out to other types of cancer. Other local government partners have used the same programme principles of the Ating Dibdibin programme for cervical cancer control.ICanServe's Ating Dibdibin programme offers valuable insights for countries facing similar challenges in breast cancer control, showing that patient-led efforts are not only viable but successful in low-income and middle-income settings.</section></section>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"12 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-03DOI: 10.1016/s1470-2045(25)00005-1
Peter Ranscombe
No Abstract
{"title":"Sharing a personal story behind brain cancer","authors":"Peter Ranscombe","doi":"10.1016/s1470-2045(25)00005-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00005-1","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1016/s1470-2045(25)00127-5
Tony Kirby
No Abstract
无摘要
{"title":"UK sees almost 30 000 extra cancer deaths each year due to deprivation","authors":"Tony Kirby","doi":"10.1016/s1470-2045(25)00127-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00127-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"85 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1016/s1470-2045(25)00017-8
Edward Christopher Dee, Mathieu Laversanne, Nirmala Bhoo-Pathy, Frances Dominique V Ho, Erin Jay G Feliciano, Michelle Ann B Eala, Frederic Ivan L Ting, Ophira Ginsburg, Fabio Ynoe Moraes, Bishal Gyawali, Scarlett Lin Gomez, Kenrick Ng, James Fan Wu, Urvish Jain, Bhav Jain, Rod Carlo Columbres, Tomohiro Matsuda, Suleeporn Sangrajrang, Evlina Suzanna Sinuraya, Tung Duc Bui, Freddie Bray
<h3>Background</h3>Cancer is a leading cause of morbidity and mortality in southeast Asia. We aimed to present and interpret cancer incidence and mortality statistics in the 11 constituent countries of Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Viet Nam to inform research priorities, health services, and cancer policy.<h3>Methods</h3>The number of new incident cases and deaths for all cancers combined and for leading cancers were extracted from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries in southeast Asia. For comparison, we extracted estimates from China, India, Japan, Pakistan, South Korea, and the USA. We estimated age-standardised incidence rates (ASIRs) and age-standardised mortality rates (ASMRs) per 100 000 person-years; projections to 2050 were also estimated by multiplying ASIR and ASMR estimates for 2022 by the expected population for 2050. Data on race or ethnicity were not collected.<h3>Findings</h3>Data were extracted on Dec 5, 2024. For the 11 countries in southeast Asia for all cancers combined, 545 725 (47·6%) of a total of 1 146 810 incident cases were estimated in men and 601 085 (52·4%) incident cases were estimated in women in 2022. In the same period, 385 430 (53·8%) of a total of 716 116 deaths were estimated in men and 330 686 (46·2%) deaths were estimated in women. The total cancer ASIR in men and women was highest in Singapore (235·89 per 100 000 and 231·01 per 100 000 respectively), while the corresponding ASMR was greatest in Laos for men (132·91 per 100 000) and Brunei for women (104·20 per 100 000). Breast cancer was the most common cancer among women in all countries (highest ASIRs in Singapore [72·61 per 100 000] and the Philippines [60·34 per 100 000]), and the most common cause of cancer mortality among women in the Philippines (ASMR 21·47 per 100 000), Malaysia (19·30 per 100 000), Singapore (17·82 per 100 000), Viet Nam (14·67 per 100 000), Indonesia (14·35 per 100 000), and Timor-Leste (10·24 per 100 000). Among men, lung cancer was the most frequently diagnosed cancer in the Philippines (ASIR 37·66 per 100 000), Malaysia (23·23 per 100 000), Myanmar (21·59 per 100 000), and Indonesia (21·30 per 100 000), and the leading cause of death due to cancer in the Philippines (ASMR 33·59 per 100 000), Singapore (31·94 per 100 000), Brunei (23·84 per 100 000), Malaysia (20·42 per 100 000), Myanmar (19·91 per 100 000), Indonesia (18·96 per 100 000), and Timor-Leste (12·95 per 100 000). Liver cancer contributed the greatest incidence and mortality in men in Cambodia, Laos, Viet Nam, and Thailand, and was also the leading cause of death due to cancer among women in Laos (ASMR 13·49 per 100 000), Cambodia (13·34 per 100 000), and Thailand (12·14 per 100 000). Cervical cancer was the leading cause of death due to cancer in women in Myanmar (ASMR 13·37 per 100 000); colorectal cancer was the most comm
{"title":"Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis","authors":"Edward Christopher Dee, Mathieu Laversanne, Nirmala Bhoo-Pathy, Frances Dominique V Ho, Erin Jay G Feliciano, Michelle Ann B Eala, Frederic Ivan L Ting, Ophira Ginsburg, Fabio Ynoe Moraes, Bishal Gyawali, Scarlett Lin Gomez, Kenrick Ng, James Fan Wu, Urvish Jain, Bhav Jain, Rod Carlo Columbres, Tomohiro Matsuda, Suleeporn Sangrajrang, Evlina Suzanna Sinuraya, Tung Duc Bui, Freddie Bray","doi":"10.1016/s1470-2045(25)00017-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00017-8","url":null,"abstract":"<h3>Background</h3>Cancer is a leading cause of morbidity and mortality in southeast Asia. We aimed to present and interpret cancer incidence and mortality statistics in the 11 constituent countries of Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, and Viet Nam to inform research priorities, health services, and cancer policy.<h3>Methods</h3>The number of new incident cases and deaths for all cancers combined and for leading cancers were extracted from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries in southeast Asia. For comparison, we extracted estimates from China, India, Japan, Pakistan, South Korea, and the USA. We estimated age-standardised incidence rates (ASIRs) and age-standardised mortality rates (ASMRs) per 100 000 person-years; projections to 2050 were also estimated by multiplying ASIR and ASMR estimates for 2022 by the expected population for 2050. Data on race or ethnicity were not collected.<h3>Findings</h3>Data were extracted on Dec 5, 2024. For the 11 countries in southeast Asia for all cancers combined, 545 725 (47·6%) of a total of 1 146 810 incident cases were estimated in men and 601 085 (52·4%) incident cases were estimated in women in 2022. In the same period, 385 430 (53·8%) of a total of 716 116 deaths were estimated in men and 330 686 (46·2%) deaths were estimated in women. The total cancer ASIR in men and women was highest in Singapore (235·89 per 100 000 and 231·01 per 100 000 respectively), while the corresponding ASMR was greatest in Laos for men (132·91 per 100 000) and Brunei for women (104·20 per 100 000). Breast cancer was the most common cancer among women in all countries (highest ASIRs in Singapore [72·61 per 100 000] and the Philippines [60·34 per 100 000]), and the most common cause of cancer mortality among women in the Philippines (ASMR 21·47 per 100 000), Malaysia (19·30 per 100 000), Singapore (17·82 per 100 000), Viet Nam (14·67 per 100 000), Indonesia (14·35 per 100 000), and Timor-Leste (10·24 per 100 000). Among men, lung cancer was the most frequently diagnosed cancer in the Philippines (ASIR 37·66 per 100 000), Malaysia (23·23 per 100 000), Myanmar (21·59 per 100 000), and Indonesia (21·30 per 100 000), and the leading cause of death due to cancer in the Philippines (ASMR 33·59 per 100 000), Singapore (31·94 per 100 000), Brunei (23·84 per 100 000), Malaysia (20·42 per 100 000), Myanmar (19·91 per 100 000), Indonesia (18·96 per 100 000), and Timor-Leste (12·95 per 100 000). Liver cancer contributed the greatest incidence and mortality in men in Cambodia, Laos, Viet Nam, and Thailand, and was also the leading cause of death due to cancer among women in Laos (ASMR 13·49 per 100 000), Cambodia (13·34 per 100 000), and Thailand (12·14 per 100 000). Cervical cancer was the leading cause of death due to cancer in women in Myanmar (ASMR 13·37 per 100 000); colorectal cancer was the most comm","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.1016/s1470-2045(25)00126-3
Karl Gruber
No Abstract
无摘要
{"title":"New agreement aims to eliminate cervical cancer across the Americas","authors":"Karl Gruber","doi":"10.1016/s1470-2045(25)00126-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00126-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-25DOI: 10.1016/s1470-2045(25)00065-8
Wolfgang M Brueckl
No Abstract
{"title":"Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC","authors":"Wolfgang M Brueckl","doi":"10.1016/s1470-2045(25)00065-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00065-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"210 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<h3>Background</h3>Trastuzumab rezetecan (also known as SHR-A1811) is a novel antibody–drug conjugate consisting of a humanised HER2-directed monoclonal antibody, cleavable tetrapeptide-based linker, and DNA topoisomerase I inhibitor. In the phase 1 portion of this phase 1/2 study, trastuzumab rezetecan showed preliminary anti-tumour activity and a favourable safety profile in patients with <em>HER2</em>-mutant non-small-cell lung cancer (NSCLC). We present phase 2 results from the study, which aimed to further evaluate the activity and safety of trastuzumab rezetecan at the recommended dose.<h3>Methods</h3>In this multicentre, single-arm, phase 2 trial, conducted in 35 hospitals in China, we recruited patients aged 18–75 years, with locally advanced or metastatic NSCLC with an activating <em>HER2</em> mutation and an Eastern Cooperative Oncology Group performance status score of 0–1, who had disease progression after or were intolerant to platinum-based chemotherapy and anti-PD-1 treatment or anti-PD-L1 treatment. Trastuzumab rezetecan was administered at 4·8 mg/kg intravenously once every 3 weeks. The primary endpoint was objective response rate assessed by an independent review committee in patients who received at least one cycle of study treatment. All patients who received at least one cycle of study treatment were included in safety analyses. This study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, <span><span>NCT04818333</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, and is ongoing but not recruiting.<h3>Findings</h3>Between April 14, 2023, and Dec 14, 2023, 94 patients were enrolled and treated. 42 (45%) patients were male, 52 (55%) female, 92 (98%) were Han Chinese, and two (2%) were other ethnicity Chinese. At data cutoff (June 14, 2024), the median duration of follow-up was 8·7 months (IQR 7·0–10·4). 69 (73%; 95% CI 63·3–82·0) of 94 patients had a confirmed objective response, as assessed by independent review committee. The most common grade 3–4 treatment-related adverse events were decreased neutrophil count (38 [40%] patients), decreased white blood cell count (25 [27%]), anaemia (22 [23%]), decreased platelet count (10 [11%]), and decreased lymphocyte count (seven [7%]). Treatment-related serious adverse events occurred in 22 (23%) patients, which were decreased platelet count (six [6%]), decreased neutrophil count (six [6%]), interstitial lung disease (five [5%]), decreased white blood cell count (four [4%]), anaemia (four [4%]), vomiting (three [3%]), pneumonia (three [3%]), hyponatraemia (two [2%]), and pyrexia (one [1%]), small intestinal obstruction
{"title":"Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","authors":"Ziming Li, Yan Wang, Yuping Sun, Linlin Wang, Xingya Li, Longhua Sun, Zhiyi He, Haiyan Yang, Yongsheng Wang, Qiming Wang, Zhengbo Song, Wei Hong, Yong Wang, Guohao Xia, Yan Yu, Min Peng, Yong Song, Donglin Wang, Rui Meng, Jian Fang, Shun Lu","doi":"10.1016/s1470-2045(25)00012-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00012-9","url":null,"abstract":"<h3>Background</h3>Trastuzumab rezetecan (also known as SHR-A1811) is a novel antibody–drug conjugate consisting of a humanised HER2-directed monoclonal antibody, cleavable tetrapeptide-based linker, and DNA topoisomerase I inhibitor. In the phase 1 portion of this phase 1/2 study, trastuzumab rezetecan showed preliminary anti-tumour activity and a favourable safety profile in patients with <em>HER2</em>-mutant non-small-cell lung cancer (NSCLC). We present phase 2 results from the study, which aimed to further evaluate the activity and safety of trastuzumab rezetecan at the recommended dose.<h3>Methods</h3>In this multicentre, single-arm, phase 2 trial, conducted in 35 hospitals in China, we recruited patients aged 18–75 years, with locally advanced or metastatic NSCLC with an activating <em>HER2</em> mutation and an Eastern Cooperative Oncology Group performance status score of 0–1, who had disease progression after or were intolerant to platinum-based chemotherapy and anti-PD-1 treatment or anti-PD-L1 treatment. Trastuzumab rezetecan was administered at 4·8 mg/kg intravenously once every 3 weeks. The primary endpoint was objective response rate assessed by an independent review committee in patients who received at least one cycle of study treatment. All patients who received at least one cycle of study treatment were included in safety analyses. This study is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT04818333</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is ongoing but not recruiting.<h3>Findings</h3>Between April 14, 2023, and Dec 14, 2023, 94 patients were enrolled and treated. 42 (45%) patients were male, 52 (55%) female, 92 (98%) were Han Chinese, and two (2%) were other ethnicity Chinese. At data cutoff (June 14, 2024), the median duration of follow-up was 8·7 months (IQR 7·0–10·4). 69 (73%; 95% CI 63·3–82·0) of 94 patients had a confirmed objective response, as assessed by independent review committee. The most common grade 3–4 treatment-related adverse events were decreased neutrophil count (38 [40%] patients), decreased white blood cell count (25 [27%]), anaemia (22 [23%]), decreased platelet count (10 [11%]), and decreased lymphocyte count (seven [7%]). Treatment-related serious adverse events occurred in 22 (23%) patients, which were decreased platelet count (six [6%]), decreased neutrophil count (six [6%]), interstitial lung disease (five [5%]), decreased white blood cell count (four [4%]), anaemia (four [4%]), vomiting (three [3%]), pneumonia (three [3%]), hyponatraemia (two [2%]), and pyrexia (one [1%]), small intestinal obstruction ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-20DOI: 10.1016/s1470-2045(25)00093-2
Sharmila Devi
No Abstract
{"title":"Opposition to proposed US bill deemed “Cancer Gag Act”","authors":"Sharmila Devi","doi":"10.1016/s1470-2045(25)00093-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00093-2","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143462476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：